Abstract
Background Approximately 25% of all patients with bipolar disorder are considered treatment-resistant. Accelerated intermittent Theta Burst Stimulation (aiTBS) is an innovative form of repetitive transcranial magnetic stimulation (rTMS), delivering bursts of stimulation at theta wave frequencies, which are believed to enhance synaptic plasticity. This pilot study aimed to explore the safety, tolerability, and preliminary efficacy of aiTBS in individuals with treatment-resistant bipolar depression (TRBD).
Methods This open-label pilot study (Overview of Medical Research in the Netherlands (OMON): NL-OMON53634) included eight patients diagnosed with TRBD. Participants received eight daily sessions of intermittent Theta Burst Stimulation (iTBS) over five consecutive days, with 50-minute intervals between sessions. Stimulation targeted the left dorsolateral prefrontal cortex (dlPFC) using the BeamF3 targeting method. Primary outcomes were safety, tolerability, and efficacy. Safety was assessed by recording (serious) adverse events; tolerability was evaluated through side effect reports and dropout rates. Efficacy was measured as the mean reduction in depression severity, as assessed by the 17-item Hamilton Depression Rating Scale (HDRS-17).
Results aiTBS was well tolerated and no SAEs occurred during the treatment week. Most observed adverse events were discomfort at the site of stimulation and fatigue [7/8, 87.5%]. No treatment-emergent [hypo]mania was observed during intervention week or during the follow-up. One patient experienced hypomanic symptoms [YMRS=13] at the 3 month follow-up visit. The mean HDRS decreased from 22.9 [SD=4.4] at baseline to 16.6 [SD=4.2] at day 3 of treatment [difference= -6.3 (95% CI, 1.6 – 10.9); 27.3% improvement, p=0.01*], decreased significantly to 12.3 [SD=4.1] at day 5 [difference= -10.1 (95% CI, 2.2 – 18.1); 44.3% improvement, p=0.02*], decreased significantly to 11.1 [SD=3.8] at week 2 of FU [difference= -11.8 (95% CI, 4.5 – 19.0); 51.4% improvement, p=0.004**] and decreased significantly to 13.5 [SD=3.9] at week 4 of FU [difference= -9.4 (95% CI, 1.0 – 17.7); 41.0% improvement, p=0.03*].
Conclusion This study extends on the previous of rapid antidepressant effects, safety and tolerability of aiTBS in patients with TRBD. We suggest future RCTs to investigate maintenance aiTBS or tapering studies, to possibly prolongate the antidepressant effect.
Conflict of Interest declaration The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NL-OMON53634
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the Amsterdam UMC gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
